In addition, the combination treatment group had a lower proportion of tumor‐infiltrating CD8+ Tex cells and higher proportion of IFN‐γ+GzmB+ T cells in the tumor site than the anti‐PD‐1 therapy group (Figure 4E). The gene discussed is CD8A; the disease is neoplasm.